By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Foundation Medicine's today said that its genomic tests will be used by biopharmaceutical company Celgene for clinical trials of its anti-cancer drug candidates.

Foundation's test, which is under development, will be used to hasten faster recruitment of target patient populations and for broad genetic characterization of trial enrollees in order to identify patients most likely to respond to Celgene's drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.